Clinical trials: Inadequate Response
Juvenile Idiopathic Arthritis
Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan
The purpose of this study is to assess the efficacy of Abatacept after intravenous administration in Japanese children and adolescents with active juvenile idiopathic arthritis who have a history of an inadequate response or…
- Trial name
- NCT01835470
- Testing
- Abatacept
- Where
- 13 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Generalized Anxiety Disorder
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental…
- Trial name
- NCT06701903
- Testing
- ITI-1284 10 mg, ITI-1284 20 mg
- Where
- 51 sites in United States, Bulgaria and 3 more
- Volunteers
- 570 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in adult participants with major depressive disorder…
- Trial name
- VENTURA-7 (NCT06514742)
- Testing
- Aticaprant
- Where
- 84 sites in United States, Belgium and 7 more
- Volunteers
- 101 people
- Sponsor
- Janssen Research & Development, LLC
Generalized Anxiety Disorder
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic…
- Trial name
- NCT06480383
- Testing
- ITI-1284 10 mg, ITI-1284 20 mg
- Where
- 56 sites in United States, Bulgaria and 3 more
- Volunteers
- 705 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Polycythemia Vera
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Researchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone.
- Trial name
- NCT07722611
- Testing
- Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b
- Where
- 2 sites in United States, Israel
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Spontaneous Urticaria
A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
The purpose of this study is to evaluate the efficacy and safety of TAS5315 in chronic spontaneous urticaria patients with an inadequate response to H1-antihistamines
- Trial name
- NCT05335499
- Testing
- TAS5315 Dose 1, TAS5315 Dose 2, TAS5315 Dose 3
- Where
- 12 sites in Japan
- Volunteers
- 126 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
This randomized, parallel-group study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) versus adalimumab, both in combination with methotrexate (MTX) in patients with moderate to severe active rheumatoid…
- Trial name
- NCT01283971
- Testing
- tocilizumab [RoActemra/Actemra], adalimumab, methotrexate
- Where
- 170 sites in United States, Denmark and 10 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who…
- Trial name
- NCT03813199
- Testing
- ABX464 50mg, ABX464 100mg, Methotrexate
- Where
- 24 sites in Belgium, Czechia and 3 more
- Volunteers
- 60 people
- Sponsor
- Abivax S.A.
Hypertension, Pulmonary
Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor
BAY63-2521 Riociguat leads to the relaxation of smooth muscle cells in pulmonary arteria and may also inhibit abnormal remodeling of lung blood vessels.
- Trial name
- RESPITE (NCT02007629)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 61 people
- Sponsor
- Bayer
Rheumatoid Arthritis
A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
This study will assess the long-term safety and efficacy of repeating treatment with MabThera, in combination with methotrexate and steroids, in patients who were previously randomized into MabThera study WA17042.
- Trial name
- NCT02097745
- Testing
- methotrexate, rituximab [MabThera/Rituxan]
- Where
- 97 sites in United States, Belgium and 9 more
- Volunteers
- 341 people
- Sponsor
- Hoffmann-La Roche
Major Depressive Disorder, Irritability
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
To explore the anti-impulsive and anti-aggressive properties of brexpiprazole in a naturalistic setting of depressed patients with irritability.
- Trial name
- NCT01942785
- Testing
- Brexpiprazole
- Where
- 15 sites in United States
- Volunteers
- 55 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Open Label Extension for GLYX13-C-202, NCT01684163
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
- Trial name
- NCT02192099
- Testing
- Rapastinel (225 mg/450 mg IV administration)
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Rheumatoid Arthritis
A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs
The objective of this study was to verify the superiority of ASP015K alone or in combination with disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who…
- Trial name
- NCT02308163
- Testing
- Peficitinib, Etanercept
- Where
- 153 sites in Japan, South Korea and 1 more
- Volunteers
- 509 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
This is a Phase IIa/b double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of RO7123520 as adjunctive therapy in participants with RA who are inadequately responding…
- Trial name
- NCT03001219
- Testing
- Anti-TNF-alpha, Methotrexate, RO7123520
- Where
- 81 sites in United States, Argentina and 9 more
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD
This is a multicenter, randomized, double-blind, parallel, placebo- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD…
- Trial name
- NCT07423533
- Testing
- GenSci120 150 mg, GenSci120 600 mg, GenSci120 1000 mg
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Major Depressive Disorder, MDD
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant…
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT01152554
- Testing
- TC-5214
- Where
- 94 sites in United States, Puerto Rico
- Volunteers
- 813 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis, NOS
PoC in Rheumatoid Arthritis With Methotrexate
The purpose of this study is to find out if 300 mg of BMS-582949 given once daily will be more effective than placebo after 12 weeks of treatment in subjects with rheumatoid arthritis who are also taking methotrexate
- Trial name
- NCT00605735
- Testing
- BMS-582949
- Where
- 28 sites in United States, Argentina and 6 more
- Volunteers
- 121 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants
Safety and efficacy of BG9924 in RA participants that have had an inadequate response to disease-modifying anti-rheumatic drug (DMARD) therapy.
- Trial name
- RESPOND (NCT00664716)
- Testing
- Baminercept alfa 1, Baminercept alfa 2, Baminercept alfa 3
- Where
- 8 sites in Argentina, Brazil and 6 more
- Volunteers
- 391 people
- Sponsor
- Biogen
Gout
Allopurinol Combination Study
To compare the proportion of subjects whose serum urate (sUA) levels are < 6.0 mg/dL following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to allopurinol alone in subjects with documented inadequate…
- Trial name
- RDEA594-203 (NCT01001338)
- Testing
- RDEA594, Allopurinol
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 227 people
- Sponsor
- Ardea Biosciences, Inc.
Rheumatoid Arthritis
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
This was a double-blind, placebo-controlled, parallel-arm, multicentre, prospective dose-finding trial of the safety and efficacy of atacicept in subjects with active rheumatoid arthritis who had failed a three month therapeutic…
- Trial name
- AUGUST I (NCT00430495)
- Testing
- Atacicept
- Where
- 2 sites in United States, Canada
- Volunteers
- 256 people
- Sponsor
- EMD Serono